Clinical trial
Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer
NCT00347438 · University of Chicago, Other · Terminated
Key facts
| NCT number | NCT00347438 |
|---|---|
| Title | Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer |
| Official title | A Phase II Study to Evaluate the Efficacy, Safety, and Genomic Markers of Response of Capecitabine as NeoAdjuvant Therapy in Women With Newly Diagnosed Locally Advanced Breast Cancer |
| Lead sponsor | University of Chicago, Other |
| Collaborators | Breast Cancer Research Foundation Roche Pharma AG Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine |
| Enrollment | 18 |
| Start date | Sep 1, 2006 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Jul 4, 2006 |
| Last update posted | Dec 14, 2015 |
| Countries | Nigeria, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: